$276.94
6.872.54%
At Close: -
$276.94
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Bio-Rad Laboratories
BIONYSE
Bio-Rad Laboratories (NYSE:BIO) Stock, Analyst Ratings, Price Targets, Forecasts
Bio-Rad Laboratories Inc has a consensus price target of $436.67 based on the ratings of 20 analysis. The 3 most-recent analyst ratings were released by Jefferies, UBS, and Citigroup on June 3, 2024, May 8, 2024, and April 3, 2024, respectively. With an average price target of $355 between Jefferies, UBS, and Citigroup, there's an implied 28.19% upside for Bio-Rad Laboratories Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
UBS
Citigroup
RBC Capital
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Bio-Rad Laboratories
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/03/2024 | Buy Now | 13.74% | Jefferies | — | $440 → $315 | Assumes | Buy → Hold | Get Alert |
| 05/08/2024 | Buy Now | 39.02% | UBS | Dan Leonard | $420 → $385 | Maintains | Buy | Get Alert |
| 04/03/2024 | Buy Now | 31.8% | Citigroup | Patrick Donnelly | $400 → $365 | Downgrade | Buy → Neutral | Get Alert |
| 02/16/2024 | Buy Now | 51.66% | UBS | Dan Leonard | $395 → $420 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 73.32% | RBC Capital | Conor McNamara | $484 → $480 | Maintains | Outperform | Get Alert |
| 12/07/2023 | Buy Now | 42.63% | UBS | Dan Leonard | → $395 | Initiates | → Buy | Get Alert |
| 08/07/2023 | Buy Now | 89.57% | Wells Fargo | Dan Leonard | $550 → $525 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 89.21% | RBC Capital | Conor McNamara | $522 → $524 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | 98.6% | Credit Suisse | Dan Leonard | $580 → $550 | Maintains | Outperform | Get Alert |
| 06/16/2023 | Buy Now | 98.6% | Wells Fargo | Dan Leonard | → $550 | Initiates | → Overweight | Get Alert |
| 05/08/2023 | Buy Now | 89.57% | Citigroup | Patrick Donnelly | $550 → $525 | Maintains | Buy | Get Alert |
| 05/08/2023 | Buy Now | 91.74% | RBC Capital | Conor McNamara | $582 → $531 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | 109.43% | Credit Suisse | Dan Leonard | $680 → $580 | Maintains | Outperform | Get Alert |
| 02/17/2023 | Buy Now | 109.07% | RBC Capital | Conor McNamara | $571 → $579 | Maintains | Outperform | Get Alert |
| 02/17/2023 | Buy Now | 145.54% | Credit Suisse | Dan Leonard | $640 → $680 | Maintains | Outperform | Get Alert |
| 12/07/2022 | Buy Now | 104.02% | RBC Capital | Conor McNamara | → $565 | Initiates | → Outperform | Get Alert |
| 10/28/2022 | Buy Now | 131.1% | Credit Suisse | Dan Leonard | $715 → $640 | Maintains | Outperform | Get Alert |
| 08/25/2022 | Buy Now | 158.18% | Credit Suisse | Dan Leonard | → $715 | Initiates | → Outperform | Get Alert |
| 07/08/2022 | Buy Now | 152.76% | Citigroup | Patrick Donnelly | $750 → $700 | Maintains | Buy | Get Alert |
| 07/30/2021 | Buy Now | 235.81% | Wells Fargo | Dan Leonard | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Bio-Rad Laboratories (BIO) stock?
The latest price target for Bio-Rad Laboratories (NYSE:BIO) was reported by Jefferies on June 3, 2024. The analyst firm set a price target for $315.00 expecting BIO to rise to within 12 months (a possible 13.74% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bio-Rad Laboratories (BIO)?
The latest analyst rating for Bio-Rad Laboratories (NYSE:BIO) was provided by Jefferies, and Bio-Rad Laboratories their hold rating.
When was the last upgrade for Bio-Rad Laboratories (BIO)?
There is no last upgrade for Bio-Rad Laboratories
When was the last downgrade for Bio-Rad Laboratories (BIO)?
The last downgrade for Bio-Rad Laboratories Inc happened on April 3, 2024 when Citigroup changed their price target from $400 to $365 for Bio-Rad Laboratories Inc.
When is the next analyst rating going to be posted or updated for Bio-Rad Laboratories (BIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bio-Rad Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bio-Rad Laboratories was filed on June 3, 2024 so you should expect the next rating to be made available sometime around June 3, 2025.
Is the Analyst Rating Bio-Rad Laboratories (BIO) correct?
While ratings are subjective and will change, the latest Bio-Rad Laboratories (BIO) rating was a with a price target of $440.00 to $315.00. The current price Bio-Rad Laboratories (BIO) is trading at is $276.94, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.